Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The value for money of drugs and other tech

Share :

HARMONY Alliance: 3rd General Assembly for Partners and Associated Members

4 - 5 Oct 2018
Published: 26 Nov 2018
Views: 928
Rating:
Save
Prof Andrea Manca - University of York, UK, HARMONY Partner

Prof Andrea Manca speaks with ecancer at the HARMONY Project general assembly 2018 in Valencia.

He answers how HARMONY can contribute when assessing the value of technologies and drugs.

To see more from HARMONY visit their website.

Related Videos

Synthetic biology and precision medicine in blood and gynaecological cancers
Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria...
Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )
21 Dec 2023
OncoAlert Round Up for September 15-21, 2023
Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
25 Sep 2023
The use of IORT at Universitätsmedizin Mannheim hospital
Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany
The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )
2 May 2023
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...
Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )
25 Apr 2023
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...
Dr Ian Krop - Yale Cancer Center, Connecticut, USA
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )
23 Dec 2022
Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk...
Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA
Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML ( Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA )
22 Dec 2022
Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally...
Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium
Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )
11 Sep 2022
How air pollution may trigger lung cancer in never-smokers
Prof Charles Swanton - Francis Crick Institute, London, England
How air pollution may trigger lung cancer in never-smokers ( Prof Charles Swanton - Francis Crick Institute, London, England )
10 Sep 2022
Nirogacestat success for desmoid tumours
Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany
Nirogacestat success for desmoid tumours ( Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany )
10 Sep 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation